BBI Life Sciences Corp EBITDA Margin dropped on 25.5 pp from 25.5% to in 2016
24/03/2017 • About BBI Life Sciences Corp (
$1035) • By InTwits
BBI Life Sciences Corp reported FY2016 financial results today. Below you can find a comprehensive analysis of the key data driving the company's performance and stock price.
BBI Life Sciences Corp ($1035) key annual financial indicators
| mln. CNY | 2012 | 2013 | 2014 | 2015 | 2016 | 2016/2015 |
|---|
P&L
|
|---|
| Revenue | 186.4 | 220.0 | 253.2 | 282.4 | 352.0 | 24.7% |
| Gross Profit | 102.5 | 111.1 | 130.4 | 151.1 | | -100.0% |
| SG&A | 64.5 | 65.9 | 112.8 | 96.0 | | -100.0% |
| EBITDA | 48.0 | 57.2 | 31.5 | 71.9 | | -100.0% |
| Net Income | 33.4 | 40.2 | 33.3 | 50.3 | 60.2 | 19.5% |
Balance Sheet
|
|---|
| Cash | 18.2 | 47.4 | 195.8 | 349.9 | | -100.0% |
| Short Term Debt | 11.3 | 0.0 | 0.0 | 0.0 | | |
| Long Term Debt | 0.0 | 0.0 | 0.0 | 0.0 | | |
Cash flow
|
|---|
| Capex | 44.0 | 14.8 | 16.3 | 56.4 | | -100.0% |
Ratios
|
|---|
| Revenue growth | 16.4% | 18.0% | 15.1% | 11.5% | 24.7% | |
| EBITDA growth | -0.8% | 19.3% | -45.0% | 128.5% | | |
| Gross Margin | 55.0% | 50.5% | 51.5% | 53.5% | | -53.5% |
| EBITDA Margin | 25.7% | 26.0% | 12.4% | 25.5% | 0.0% | -25.5% |
| Net Income Margin | 17.9% | 18.3% | 13.1% | 17.8% | 17.1% | -0.7% |
| SG&A, % of revenue | 34.6% | 29.9% | 44.5% | 34.0% | | -34.0% |
| CAPEX, % of revenue | 23.6% | 6.7% | 6.4% | 20.0% | | -20.0% |
| ROIC | 20.7% | 17.8% | 4.6% | 10.4% | | -10.4% |
| ROE | 20.2% | 17.1% | 8.5% | 9.5% | | -9.5% |
| Net Debt/EBITDA | -0.1x | -0.8x | -6.2x | -4.9x | | 4.9x |
Revenue and profitability
BBI Life Sciences Corp's Revenue surged on 24.7%.
Net Income marign decreased slightly on 0.73 pp from 17.8% to 17.1% in FY2016.
Appendix 1: Peers in Healthcare-Products
Below we provide BBI Life Sciences Corp benchmarking against other companies in Healthcare-Products industry for the last 5 years. We show data for the top-5 companies by key financial metric together with the median value for all the companies in the industry.
Top companies by Revenue growth, %
| Top 5 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 |
|---|
| Vitop Bioenergy Holdings Ltd ($1178) | | -3.2% | -27.3% | 92.4% | 281.7% |
| Beijing Chunlizhengda Medical Instruments Co Ltd ($1858) | 22.2% | 12.8% | 21.8% | 32.0% | |
| China Medical System Holdings Ltd ($867) | | 26.5% | 31.0% | 20.7% | 37.9% |
| Shandong Weigao Group Medical Polymer Co Ltd ($1066) | | 25.1% | 14.4% | 12.1% | 13.7% |
| Lifetech Scientific Corp ($1302) | | 27.3% | 22.4% | 10.2% | 13.2% |
| |
|---|
| Median (16 companies) | 17.9% | 12.2% | 10.8% | 5.2% | 6.5% |
|---|
| BBI Life Sciences Corp ($1035) | | 18.0% | 15.1% | 11.5% | 24.7% |
Top companies by Gross margin, %
| Top 5 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 |
|---|
| Lifetech Scientific Corp ($1302) | 80.1% | 81.6% | 81.4% | 81.1% | |
| PW Medtech Group Ltd ($1358) | 66.0% | 67.9% | 72.8% | 75.1% | |
| Golden Meditech Holdings Ltd ($801) | 69.1% | 69.8% | 70.2% | 72.8% | 45.8% |
| Beijing Chunlizhengda Medical Instruments Co Ltd ($1858) | 71.6% | 72.1% | 73.8% | 68.6% | |
| Microport Scientific Corp ($853) | 83.6% | 81.0% | 68.5% | 67.2% | |
| |
|---|
| Median (16 companies) | 50.2% | 52.9% | 48.2% | 47.8% | 39.3% |
|---|
| BBI Life Sciences Corp ($1035) | 55.0% | 50.5% | 51.5% | 53.5% | |
Top companies by EBITDA margin, %
| Top 5 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 |
|---|
| PW Medtech Group Ltd ($1358) | 44.2% | 30.6% | 41.6% | 48.6% | |
| Lifetech Scientific Corp ($1302) | 31.6% | 24.5% | 23.4% | 33.1% | |
| China Medical System Holdings Ltd ($867) | 34.5% | 32.4% | 39.4% | 32.3% | 32.7% |
| Hengan International Group Co Ltd ($1044) | 27.4% | 25.3% | 25.3% | 28.0% | 27.4% |
| Shandong Weigao Group Medical Polymer Co Ltd ($1066) | 28.5% | 28.0% | 29.0% | 27.8% | 25.1% |
| |
|---|
| Median (16 companies) | 22.8% | 22.2% | 13.6% | 9.4% | 9.3% |
|---|
| BBI Life Sciences Corp ($1035) | 25.7% | 26.0% | 12.4% | 25.5% | |
Top companies by CAPEX/Revenue, %
| Top 5 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 |
|---|
| Lifetech Scientific Corp ($1302) | 0.0% | 16.5% | 0.0% | 70.0% | |
| PW Medtech Group Ltd ($1358) | 14.8% | 22.3% | 30.2% | 42.1% | |
| Arts Optical International Hldgs ($1120) | 14.0% | 4.5% | 14.0% | 29.9% | |
| Golden Meditech Holdings Ltd ($801) | 12.7% | 51.2% | 27.3% | 26.1% | 56.4% |
| Shandong Weigao Group Medical Polymer Co Ltd ($1066) | 26.0% | 20.2% | 11.7% | 18.3% | |
| |
|---|
| Median (16 companies) | 5.2% | 6.3% | 5.9% | 4.9% | 1.7% |
|---|
| BBI Life Sciences Corp ($1035) | 23.6% | 6.7% | 6.4% | 20.0% | |
Top companies by ROIC, %
| Top 5 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 |
|---|
| Lifetech Scientific Corp ($1302) | 17.5% | 15.9% | 21.2% | 32.9% | |
| China Medical System Holdings Ltd ($867) | 19.4% | 20.2% | 27.4% | 20.5% | 20.5% |
| Hengan International Group Co Ltd ($1044) | 19.5% | 14.9% | 14.0% | 16.4% | 15.4% |
| Beijing Chunlizhengda Medical Instruments Co Ltd ($1858) | 22.2% | 20.9% | 21.0% | 12.1% | |
| Shandong Weigao Group Medical Polymer Co Ltd ($1066) | 10.5% | 11.7% | 12.8% | 11.8% | 10.4% |
| |
|---|
| Median (16 companies) | 8.5% | 7.4% | 5.3% | 2.5% | 4.5% |
|---|
| BBI Life Sciences Corp ($1035) | 20.7% | 17.8% | 4.6% | 10.4% | |
Top companies by Net Debt / EBITDA
| Top 5 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 |
|---|
| Microport Scientific Corp ($853) | -1.0x | -2.8x | | 4.3x | |
| Techcomp Holdings Ltd ($1298) | 4.3x | 3.6x | 2.7x | 3.0x | |
| Hengan International Group Co Ltd ($1044) | 1.4x | 1.7x | 1.8x | 1.7x | 0.2x |
| China Medical System Holdings Ltd ($867) | -0.4x | -0.2x | 0.2x | -0.0x | 0.7x |
| PW Medtech Group Ltd ($1358) | -1.2x | -7.5x | -0.3x | -1.1x | |
| |
|---|
| Median (11 companies) | -1.2x | -1.6x | -1.5x | -1.1x | 0.2x |
|---|
| BBI Life Sciences Corp ($1035) | -0.1x | -0.8x | -6.2x | -4.9x | |
